Pfizer (PFE) Tops Q4 EPS by 20c, Revenue Misses, Guidance Falls Short of Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report
February 8, 2022 7:47 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE), following the company's most recent earnings report.
The analyst quotes: "Good Enough 4Q21 results driven by an EPS beat; 2022 Guide light, but we see room... More
Pfizer (PFE) Reiterated at Overweight by Cantor Fitzgerald, "Confident PFE Can Meet its Guidance for a 5-year Revenue CAGR of at least 6%"
February 8, 2022 7:21 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $75.00 price target on Pfizer (NYSE: PFE), following the company's most recent earnings report.
The analyst quotes: "Post a mixed 4Q21 report (sales miss, fewer selling days and EPS beat), we are... More
